DSight discovers and develops novel treatments targeting neurodegenerative diseases affecting the retina. The company focuses on a first-in-class, cost-effective, and non-invasive solution for the prevention and early treatment of diabetic retinopathy. This approach aims to improve patient quality of life by avoiding limitations associated with current standard-of-care therapies.
Funding
$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diabetic retinopathy, a common complication of diabetes, can lead to preventable blindness, particularly in the working-age population. Current standard-of-care therapies may have limitations and side effects, creating a need for safer and more effective early-stage interventions. The rising prevalence of diabetes globally is increasing the number of individuals at risk for developing diabetic retinopathy.
Solution
D-Sight is developing a non-invasive treatment designed to prevent the progression of early-stage diabetic retinopathy. Their solution aims to address the unmet medical need for a cost-effective and safe therapy that avoids the side effects associated with existing treatments. By targeting the neurodegenerative aspects of retinal disease associated with diabetes, D-Sight hopes to improve the quality of life for diabetic patients and reduce the incidence of vision loss. The treatment is designed to be easily administered and integrated into existing clinical workflows.
Target Audience
The primary target audience includes diabetic patients at risk of or in the early stages of developing diabetic retinopathy, as well as ophthalmologists and healthcare providers specializing in diabetic eye care.
Features
- Non-invasive treatment approach
- Focus on early-stage diabetic retinopathy
- Designed to prevent retinal neurodegeneration
- Aims to be cost-effective compared to current treatments
- Seeks to minimize side effects and limitations of existing therapies